Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Jazz Pharmaceuticals (JAZZ)

Jazz Chief Commercial Officer Samantha Pearce to retire; successor search planned

Neutral Impact 3 of 5 leadership Written later

Jazz Pharmaceuticals said its Executive Vice President and Chief Commercial Officer, Samantha Pearce, notified the company on October 6, 2026 that she intends to retire. She will leave when a successor is appointed or by June 30, 2027, whichever comes first. The company plans a formal search that will consider internal and external candidates, so the change in a key commercial leadership role will take effect over time.

Key points

  • Samantha Pearce notified Jazz of her intent to retire on October 6, 2026.
  • Retirement takes effect on the earlier of her successor's appointment or June 30, 2027.
  • Jazz plans a formal search that will consider both internal and external candidates.

The filing

CompanyJazz Pharmaceuticals (JAZZ)
Form8-K, current report
Filed with the SECOct 9, 2026, 9:02 AM ET
Accession number0001628280-26-065497

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:11 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 09, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.